Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.
Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.
The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
- Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future
- NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib